Cargando…
Development of an Improved Epstein-Barr Virus (EBV) Neutralizing Antibody Assay to Facilitate Development of a Prophylactic gp350-Subunit EBV Vaccine
No licensed vaccine is available for prevention of EBV-associated diseases, and robust, high-throughput bioanalytical assays are needed to evaluate immunogenicity of gp350 subunit-based candidate EBV vaccines. Here we have developed an improved EBV-GFP based neutralization assay for such a vaccine’s...
Autores principales: | Liu, Hui, Gemmell, Lorraine, Lin, Rui, Zuo, Fengrong, Balfour, Henry H., Woo, Jennifer C., Hayes, Gregory M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059750/ https://www.ncbi.nlm.nih.gov/pubmed/32180911 http://dx.doi.org/10.4084/MJHID.2020.016 |
Ejemplares similares
-
CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease
por: Slabik, Constanze, et al.
Publicado: (2020) -
Declining Epstein-Barr Virus Antibody Prevalence in College Freshmen Strengthens the Rationale for a Prophylactic EBV Vaccine
por: Balfour, Henry H., et al.
Publicado: (2022) -
Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV
por: Venturini, Cristina, et al.
Publicado: (2021) -
Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders
por: Dugan, James P., et al.
Publicado: (2019) -
Epstein-Barr Virus (EBV)-Associated Haemophagocytic Syndrome
por: Torti, Lorenza, et al.
Publicado: (2012)